EMJ Oncology 9 [Supplement 1] . 2021

In this issue

FOUR leading experts in the field of oncology were brought together in an interview to discuss the epidemiology, treatment decisions, and emerging treatment paradigms of EGFR-mutated advanced non-small cell lung cancer (NSCLC). Recent clinical evidence was also reviewed, including the RELAY trial.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.